Physician profile
Sarah E Tonelli
NPI 1235576075
$39,556.97
in general payments reported to CMS, 2019-2025
30 companies · $31K in 2025
The $31K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $24.56 · 2021: $692 · 2022: $3,204 · 2023: $2,300 · 2024: $1,754 · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $4,382 · Consulting Fee: $1,525 · Travel and Lodging: $1,517 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,800.00 |
| Food and Beverage | $4,382.16 |
| Consulting Fee | $1,525.00 |
| Travel and Lodging | $1,517.18 |
| Education | $237.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $29,553.14 | 2019-2025 | Nemluvio, Aklief, Dysport |
| Epi Health, LLC | $1,684.49 | 2022 | |
| Abbvie INC. | $1,395.98 | 2019-2025 | Skyrizi, Rinvoq |
| Leo Pharma INC. | $904.62 | 2022-2025 | Adbry |
| Dermavant Sciences, INC. | $810.47 | 2022-2024 | Vtama |
| Janssen Biotech, INC. | $748.33 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Genzyme Corporation | $679.13 | 2021-2024 | |
| Lilly USA, LLC | $533.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma As | $450.00 | 2022 | |
| Teladoc Health, INC. | $450.00 | 2024-2025 | |
| Incyte Corporation | $387.23 | 2022-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $315.96 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $282.03 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $181.53 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $154.79 | 2022-2025 | Otezla, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $145.36 | 2023-2025 | |
| Organon LLC | $111.26 | 2025 | Vtama |
| Novartis Pharmaceuticals Corporation | $108.65 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $107.03 | 2022-2025 | Sotyktu |
| Allergan, INC. | $97.33 | 2019 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.91 | 2024-2025 | Spevigo |
| Almirall LLC | $67.40 | 2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $66.35 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $54.81 | 2022-2024 | |
| Musculoskeletal Transplant Foundation INC. | $25.22 | 2024 | |
| Botanix Sb INC | $25.18 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $24.56 | 2020 | |
| Sensus Healthcare, INC. | $23.13 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $13.03 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Tonelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.